Baseline Immunological Profile in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial

被引：0
|
作者：
Mao-Draayers, Yang [2 ]
Wu, Qi
Wang, Qin
Dowling, Catherine
Lundy, Steven [3 ,4 ]
Segal, Benjamin [2 ]
Wallstrom, Wallstrom [1 ]
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Univ Michigan, Dept Neurol, Ann Arbor, MI USA
[3] Univ Michigan, Sch Med, Dept Internal Med, Div Rheumatol, Ann Arbor, MI USA
[4] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI USA
来源：
NEUROLOGY | 2016年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P3.046
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Immunological profile of patients with primary progressive multiple sclerosis -: Expression of adhesion molecules
    Durán, I
    Martínez-Cáceres, EM
    Río, J
    Barberá, N
    Marzo, ME
    Montalban, X
    [J]. BRAIN, 1999, 122 : 2297 - 2307
  • [22] Interferon inducible transcriptional profile in secondary progressive multiple sclerosis patients
    Gurevich, M.
    Miron, G.
    Hanael, E.
    Sonis, P.
    Dolev, M.
    Magalashvili, D.
    Achiron, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 176 - 176
  • [23] Uncoupling the Impact on Relapses and Disability Progression: Siponimod in Relapsing and Non-relapsing Patients With Secondary Progressive Multiple Sclerosis in the Phase III EXPAND Study
    Cree, Bruce
    Fox, Robert
    Giovannoni, Gavin
    Vermersch, Patrick
    Bar-Or, Amit
    Gold, Ralf
    Magnusson, Baldur
    Rouyrre, Nicolas
    Meier, Daniela Piani
    Tomic, Davorka
    Karlsson, Goeril
    Dahlke, Frank
    Kappos, Ludwig
    [J]. NEUROLOGY, 2018, 90
  • [24] Effect of Siponimod on Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Phase 3 EXPAND Study Subgroup Analysis
    Benedict, Ralph
    Fox, Robert
    Tomic, Davorka
    Cree, Bruce
    Vermersch, Patrick
    Giovannoni, Gavin
    Bar-Or, Amit
    Gold, Ralf
    Ritter, Shannon
    Karlsson, Goeril
    Wolf, Christian
    Kappos, Ludwig
    [J]. NEUROLOGY, 2019, 92 (15)
  • [25] The EXPAND study results: Efficacy of siponimod in secondary progressive multiple sclerosis
    Vermersch, P.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Arnould, S.
    Wallstroem, E.
    Sidorenko, T.
    Wolf, C.
    Dahlke, F.
    Kappos, L.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 44 - 44
  • [26] Oral teriflunomide in patients with relapsing multiple sclerosis: baseline clinical features of patients in the TEMSO phase III trial
    O'Connor, Paul
    Confavreux, Christian
    Comi, Giancarlo
    Kappos, Ludwig
    Wolinsky, Jerry
    Olsson, Tomas P.
    Miller, Aaron
    Freedman, Mark S.
    [J]. MULTIPLE SCLEROSIS, 2008, 14 : S85 - S85
  • [27] FACTORS INFLUENCING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS USING EXPAND TRIAL DATA
    Vadapalle, S.
    Vudumula, U.
    Gudala, K.
    Adlard, N. E.
    [J]. VALUE IN HEALTH, 2019, 22 : S755 - S755
  • [28] Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis (SPMS): baseline characteristics of the EXPAND study population
    Kappos, L.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Vermersch, P.
    Bhasin, P.
    Arnould, S.
    Sidorenko, T.
    Wallstroem, E.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 317 - 318
  • [29] Mitoxantrone in progressive multiple sclerosis: MRI results of the European Phase III trial
    Krapf, H
    Morrissey, SP
    Zenker, O
    Zwingers, T
    Gonsette, R
    Hartung, HP
    [J]. NEUROLOGY, 1999, 52 (06) : A495 - A495
  • [30] The Pharmacokinetics of Lipoic Acid at Baseline and 48 Weeks in Secondary Progressive Multiple Sclerosis Patients
    Bittner, Frank
    Murchison, Charles
    Bourdette, Dennis
    Spain, Rebecca
    [J]. ANNALS OF NEUROLOGY, 2016, 80 : S117 - S117
12345